Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care (Q33279245)

25 July 2017

title

Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care (English)

1 reference

25 July 2017

1 reference

1 reference

M Fung-Kee-Fung

1

1 reference

25 July 2017

D Provencher

2

1 reference

25 July 2017

B Rosen

3

1 reference

25 July 2017

P Hoskins

4

1 reference

25 July 2017

L Rambout

5

1 reference

25 July 2017

T Oliver

6

1 reference

25 July 2017

W Gotlieb

7

1 reference

25 July 2017

A Covens

8

1 reference

25 July 2017

IP Chemotherapy Working Group/Society of Gynecologic Oncologists of Canada

9

1 reference

25 July 2017

language of work or name

English

0 references

publication date

21 March 2007

1 reference

25 July 2017

1 reference

25 July 2017

volume

105

1 reference

25 July 2017

issue

3

1 reference

25 July 2017

page(s)

747-756

1 reference

25 July 2017

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

The impact of subspecialty training on the management of advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

A review: intraperitoneal cisplatin in the management of patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Intraperitoneal drug delivery of antineoplastics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Intraperitoneal chemotherapy in advanced ovarian cancer: recognition at last

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Complications associated with intraperitoneal chemotherapy catheters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Intraperitoneal chemotherapy in ovarian cancer remains experimental

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Ovarian cancer--can intraperitoneal therapy be regarded as new standard in Germany?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Integration of new or experimental treatment options and new approaches to clinical trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

Intraperitoneal chemotherapy for advanced epithelial ovarian cancer: A Canadian perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.015

10.1016/J.YGYNO.2007.02.015

7 January 2021

Identifiers

DOI

1 reference

25 July 2017

1 reference